Novavax ($NVAX) Pharmaceuticals is a biotechnology company that develops vaccines. The company is in clinical development and is focused on delivering novel products to prevent a wide range of diseases. Novavax works with its wholly owned Swedish subsidiary to produce vaccine candidates to address known and emerging disease threats. The company believes that its vaccine technology has the potential to be widely applicable to a wide range of human infectious diseases. The company manages its business as one operating unit, namely, the development and commercialization of vaccines. The company generates its largest revenue from Europe.
Buy rating, target price $11
Weekly Featured Inventory
High-quality stocks on December 27, 2024($NVAX)
